Lysine analogues- chloromethyl ketones
Already in 1981 a medicinal chemist at Bayer in Wuppertal, Germany [Gerd Reinhardt, Ann. N.Y. Acad. Sci. 1981, 370, 836.] designed a series of direct acting Factor XIIIa blockers. According to the author the molecule combines the substrate amine architecture (Lysine co-substrate) with the chemical reactivity of the sulfhydryl reagent (active site cysteine attacking the chloromethyl ketone). The compound inhibits at least tissue transglutaminase as well.
Art. No.
Name
Quantity
Price
Artikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
Preview: Catalogue Editorial 2019
Microbial transglutaminase: from discovery to market
Tissue transglutaminase inhibitors
Tissue transglutaminase in Alzheimer’s Disease
Factor XIIIa: novel target for anticoagulation?
Microbial transglutaminase for site-specific protein conjugation
Transglutaminase antibodies in ataxia